PATENT CLAIM ANALYSIS

Application Number: 16128312
Application Type: Utility
Filing Date: 2018-09
Publication Date: 2019-01
Patent Classification: ["514", "001000"]

Abstract:
Described herein are pharmaceutical formulations of Bruton's tyrosine kinase (Btk) inhibitor 1-((R)-3-(4-amino-3-(4-phenoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl)piperidin-1-yl)prop-2-en-1-one. Also disclosed are methods of using the Btk inhibitor, alone or in combination with other therapeutic agents, for the treatment of autoimmune diseases or conditions, heteroimmune diseases or conditions, cancer, including lymphoma, and inflammatory diseases or conditions.

Claim (Index 28):
The high-load solid tablet formulation of  claim 27 , wherein the surfactant is sodium lauryl sulfate.

Metadata:
- Claim Count in Document: 89.0
- Percentile: 97.0
- Lexical Diversity: 1.51923
- Patent Class: 514.0
- Transitional Phrase Type: none
- Component Type: 0
- Foreign Priority: False
- Related Applications: ['15060010', '15909779', '15462444', '14821290', '15970721']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.7606997348334047
- 35 USC 102 Novelty (BERT): 0.5950497506501436
- Combined Prediction Score: 0.7441347364150787
- Mean Citation Score: 457.25797400000016
- Max Citation Score: 556.6536
- Similarity Product: 404.4570356225967

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 1
- Claim Label 112: 1
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test